Avances terapéuticos en el manejo del ameloblastoma. Scoping Review
Cargando...
Archivos
Fecha
2020
Profesor/a Guía
Facultad/escuela
Idioma
es
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad Andrés Bello
Nombre de Curso
Licencia CC
Licencia CC
Resumen
El objetivo de este artículo es revisar la evidencia disponible respecto a los avances en el tratamiento del ameloblastoma y sus eventuales consideraciones terapéuticas. Se realizó una búsqueda amplia de la literatura en bases de datos como PubMed/ MEDLINE, Cochrane, Scielo y Scopus para identificar artículos publicados en el idioma inglés entre los años 2014 y 2020. Los criterios de selección para los artículos incluyen ameloblastoma, mutación genética BRAF, Vemurafenib, Dabrafenib, Trametinib. Se extrajo la evidencia relevante y actualizada y se evaluó detalladamente, para luego ser analizada y sintetizada. Finalmente, se incluyeron 8 documentos de los 28 revisados, y 2 libros con literatura complementaria recomendada. A modo de conclusión, a pesar de ser un aporte que ha traído este avance para el manejo del ameloblastoma, aún faltan más estudios que demuestren su beneficio clínico, dificultando su avance progresivo.
The objective of this article is to review the available evidence regarding advances in the treatment of ameloblastoma and its eventual therapeutic considerations. An extensive literature search was carried out in databases such as PubMed / MEDLINE, Cochrane, Scielo, and Scopus to identify articles published in the English language between 2014 and 2020. The Selection criteria for articles include ameloblastoma, BRAF gene mutation, Vemurafenib, Dabrafenib, Trametinib. Relevant and updated evidence was extracted and evaluated in detail, to later be analyzed and synthesized. Finally 8 documents were included out of the 28 reviewed and 2 books with recommended complementary literature. In conclusion, despite being a contribution that has brought this advance to the management of ameloblastoma, more studies are still needed to demonstrate its clinical benefit, hindering its progressive advance.
The objective of this article is to review the available evidence regarding advances in the treatment of ameloblastoma and its eventual therapeutic considerations. An extensive literature search was carried out in databases such as PubMed / MEDLINE, Cochrane, Scielo, and Scopus to identify articles published in the English language between 2014 and 2020. The Selection criteria for articles include ameloblastoma, BRAF gene mutation, Vemurafenib, Dabrafenib, Trametinib. Relevant and updated evidence was extracted and evaluated in detail, to later be analyzed and synthesized. Finally 8 documents were included out of the 28 reviewed and 2 books with recommended complementary literature. In conclusion, despite being a contribution that has brought this advance to the management of ameloblastoma, more studies are still needed to demonstrate its clinical benefit, hindering its progressive advance.
Notas
Trabajo de titulación (Cirujano Dentista, Licenciado en Odontología)
Palabras clave
Cáncer de Boca, Terapias Alternativas, Enfermedades de la Boca (Mutación), Ameloblastoma, Vemurafenib, Dabrafenib, Trametinib, Chile